title: Autologous reconstitution combined with durable leukemic remission after allogeneic BMT for CML: absence of persistence of a donor-derived T cell effector population.
abstract: We report a case of autologous hematopoietic recovery with durable leukemic remission after BMT from a phenotypically HLA-identical donor in a 30-year-old male with CML. Graft loss was diagnosed from day 60 post-BMT by VNTR PCR. To assess for the presence of a minor donor-derived T cell population that could exert an anti-leukemic effect, we serially applied a sensitive process of chimerism analysis by fluorescent PCR on sorted T cells. No residual donor T cells could be detected. We also showed retrospectively that a very sensitive method of MRD analysis by real-time quantitative PCR could have permitted prediction of relapse in this case.
authors.affiliation: Department of Hematology, Henri Mondor Hospital, 94010, Créteil Cedex, France.
authors.forename: S
authors.initials: S
authors.lastname: Maury
authors.forename: K
authors.initials: K
authors.lastname: Belhadj
authors.forename: I
authors.initials: I
authors.lastname: Chami
authors.forename: M
authors.initials: M
authors.lastname: Kuentz
authors.forename: C
authors.initials: C
authors.lastname: Cordonnier
authors.forename: D
authors.initials: D
authors.lastname: Bories
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics; D001853:Bone Marrow / Q000737:chemistry / Q000473:pathology*; D016026:Bone Marrow Transplantation; D002470:Cell Survival; D003131:Combined Modality Therapy; D004273:DNA, Neoplasm / Q000235:genetics; D016044:Fusion Proteins, bcr-abl / Q000032:analysis / Q000235:genetics; D006085:Graft Survival; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D016898:Interferon-alpha / Q000008:administration & dosage; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D015466:Leukemia, Myeloid, Chronic-Phase / Q000473:pathology / Q000628:therapy; D008297:Male; D018598:Minisatellite Repeats; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D018365:Neoplasm, Residual; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics; D012074:Remission Induction; D016879:Salvage Therapy; D012680:Sensitivity and Specificity; D016176:T-Lymphocyte Subsets / Q000473:pathology*; D019172:Transplantation Conditioning
chemical_list: D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D016898:Interferon-alpha; D012333:RNA, Messenger; D016044:Fusion Proteins, bcr-abl; D006918:Hydroxyurea